HIV infections acquired while on injectable PrEP may take a very long time to be spotted
Promising new PrEP method undergoes first safety study for anal sex
Combinations containing TAF and cobicistat linked to physical depression symptoms in women with HIV
San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
Switching to injectable cabotegravir and rilpivirine rarely affects body weight
Sharing anti-HIV medication is common in rural Uganda
First, second, and third generation smallpox vaccines all protect against mpox infection
Dolutegravir plus darunavir superior to three-drug darunavir combination in second-line treatment
Good news for women and PrEP: quarterly dosing may work
